相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction
Jian Ye et al.
BMC BIOINFORMATICS (2012)
Risk of Tacrolimus Toxicity in CYP3A5 Nonexpressors Treated With Intravenous Nicardipine After Kidney Transplantation
David K. Hooper et al.
TRANSPLANTATION (2012)
Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes
Beatriz Tavira et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
CYP3A5, ABCB1, and SLCO1B1 Polymorphisms and Pharmacokinetics and Virologic Outcome of Lopinavir/Ritonavir in HIV-Infected Children
Natella Y. Rakhmanina et al.
THERAPEUTIC DRUG MONITORING (2011)
Pharmacogenetics of antiretrovirals
Valerio Tozzi
ANTIVIRAL RESEARCH (2010)
Pharmacogenomics of CYP3A: considerations for HIV treatment
Sukhwinder S. Lakhman et al.
PHARMACOGENOMICS (2009)
Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil
E. Sprinz et al.
HIV MEDICINE (2008)
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
Caroline Solas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
F. Josephson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates:: Guidelines from an experimental study
V. Haufroid et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Clinical implications of CYP3A polymorphisms
Leszek Wojnowski et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5
SJ Mouly et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests
SJ Lee et al.
PHARMACOGENOMICS (2005)
Mechanism-based inactivation of CYP3A by HIV protease inhibitors
CS Ernest et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
M Fröhlich et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
M Ingelman-Sundberg
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Increased transcriptional activity of the CYP3A4* 1B promoter variant
B Amirimani et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2003)
Genetic contribution to variable human CYP3A-mediated metabolism
JK Lamba et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity
E Garcia-Martin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
分享论文
